Investor Relations
Listed On The Shanghai Stock Exchange In June 2001, With A Maximum Market Value Of 47.5 Billion
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining Drug Registration Certificate of Voriconazole for Injection
Time：2023-01-31
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Number of Underlying Shares in Respect of the Outstanding GDRs Being less than 50% of the Number Approved by the CSRC
Time：2023-01-30
Ad hoc announcement pursuant to Art. 53 LR-JACRE Announcement on Grant of Registration Approval for Tocilizumab Injection
Time：2023-01-19
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Approval for Clinical Trials of Asenapine Transdermal Patch
Time：2023-01-13
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Upcoming Expiration of the Redemption Lock-up Period of GDRs
Time：2023-01-13
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Setting Up of a Joint Venture with Its Controlled Subsidiary Livzon Group
Time：2022-12-12
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Co-Investment with Livzon Group, the Controlled Subsidiary
Time：2022-11-28
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Resolutions of 2022 Fourth Extraordinary General Meeting
Time：2022-11-18
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining Approval Notice for Clinical Trial on Ilaprazole Tablets of Enteric-Coated Pellets
Time：2022-11-03
Ad hoc announcement pursuant to Art. 53 LR-JCARE Notice of 2022 Fourth Extraordinary General Meeting
Time：2022-10-26
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.